SequelSEC

Innoviva, Inc. INVA

Pharmaceutical Preparations · CIK 0001080014 · Fiscal year ends 1231

Revenue
$440.00M
Fiscal year ended 2026-06-30
Operating income
$162.58M
Fiscal year ended 2026-06-30
Free cash flow
$189.44M
Fiscal year ended 2026-06-30

Innoviva, Inc. (INVA) reported revenue of $440.00M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Innoviva, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Innoviva, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$440.00M
Cost of revenueUnavailable
Gross profit$317.66M
Operating income$162.58M
Net incomeUnavailable
Research & development$28.66M
Weighted-average diluted sharesUnavailable
Pretax income$419.40M
Income tax expense$62.16M
Diluted EPSUnavailable
Selling, general & administrative$126.42M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Innoviva, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$570.39M
Total assets$1.70B
Current assets$753.37M
Total liabilitiesUnavailable
Current liabilities$47.06M
Total equity incl. NCI$1.23B
Temporary (mezzanine) equityUnavailable
Inventory$38.97M
Accounts receivable$50.83M
Goodwill$17.90M
Long-term debt$258.45M
Accounts payable$4.02M

Cash flow

Innoviva, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$191.49M
Capital expenditures$2.05M
Investing cash flow$23.79M
Financing cash flow-$42.43M
Net change in cash$172.86M
Stock-based compensation$12.19M
Common dividends paidUnavailable
Common share repurchases$55.85M
Depreciation & amortizationUnavailable

Derived

Innoviva, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$189.44M
Gross margin72.2%
Operating margin36.9%
FCF margin43.1%
SBC / revenue2.8%
Current ratio16.01x
Revenue YoY growth18.8%
Net marginUnavailable
R&D / revenue6.5%
CapEx / revenue0.5%
Long-term debt / equity0.21x
Effective tax rate14.8%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open INVA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.